You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205001 - 205010 of 207712 results
  1. Understanding the Spread and Influence of Online Video Content

    SBC: OCTANT DATA, LLC            Topic: AFX235CSO1

      Graphika is the leader in social network mapping to help our clients and partners expertly navigate the online cybersocial terrain. Graphika’s revolutionary AI and ML technologies detect the most impactful narratives shaping opinions in influential comm

    SBIR Phase I 2023 Department of DefenseAir Force
  2. Determining Causality between Online and Offline Behavior

    SBC: OCTANT DATA, LLC            Topic: X22DOTCSO1

      Causal inference is a mathematical approach that enables the ability to understand how malign information operations online effectively seed and/or produce offline movements amongst a target population. This capability can tie explicit factors of an influence campaign to why a target population takes a certain side or more importantly, an offline action - e.g. starts a riot, ensures in person v ...

    STTR Phase I 2023 Department of DefenseAir Force
  3. Advanced social network engagement effectiveness monitoring

    SBC: OCTANT DATA, LLC            Topic: AF203CSO1

    Adversaries and competitors of the United States are increasingly leveraging the rapidly evolving Information Environment (IE) to advance their strategic interests against those of the US and allied nations. Maintaining an information advantage in the progressively fragmented online landscape is challenging, as the impact of activities in the IE are difficult to discern and “real-world” effect ...

    SBIR Phase II 2023 Department of DefenseSpecial Operations Command
  4. Analyzing Narrative Evolution Across Social Networks

    SBC: OCTANT DATA, LLC            Topic: SOCOM234001

    Octant’s social media network mapping and content modeling approaches will be leveraged to create high-resolution models of information environments spanning key neighboring countries, issues, and state media sources likely to be targeted by information and influence operations. These models will enable the ability to rapidly understand the narratives being spread through the network and how the ...

    SBIR Phase I 2023 Department of DefenseSpecial Operations Command
  5. A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: NIDA

    Project Summary Abstract This SBIR application is proposed in response to RFA DAthe HEAL Initiative on building technologies to stop the opioid crisisCreative Bio PeptidesIncis committed to providing effective and safe non opioid treatments for themillion Americans suffering daily pain and themillion who live with opioid dependency or addictionCurrent decades old addiction treatments like methadon ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: NIA

    7. Project Summary In response to PAS-19-319, Creative Bio-Peptides, Inc. will develop the multi-chemokine receptor (CCR2/CCR5/CXCR4) antagonist peptide R103 to prevent, even reverse, synapse loss and neurodegeneration relevant to Alzheimer’s Disease (AD). Functional impairment in AD results from loss of neuronal spines and dendrites, preceding and independent of neuronal death. Cofilin-actin ro ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: 106

    7. Project Summary In response to RFS-NS-20-11, Creative Bio-Peptides, Inc. will develop the multi-chemokine receptor antagonist peptide R103 to provide a non-opioid, potentially disease modifying treatment for neuropathic pain conditions. We have completed proof-of-concept (POC) animal studies in neuropathic pain by partial nerve ligation and diabetes. We will conduct a further POC study of R103 ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: NIA

    7. Project Summary AD In response to PAS-19-319, Creative Bio-Peptides, Inc. proposes a novel therapeutic approach to protect and restore synapses in Alzheimer’s Disease (AD) by blocking multiple chemokine receptors that promote synapse loss and inhibit their regeneration. Functional impairment in AD results from loss of neuronal spines and dendrites, preceding and independent of neuronal death. ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: NIDA

    7. Project Summary Over 2.1 million Americans suffer from opioid use disorder (OUD) resulting in 47,000 deaths annually. Individuals seeking treatment must deal with limited access to qualified healthcare professionals, as well as barriers to getting medication assisted treatment (MAT). Common MAT treatments utilizing buprenorphine often require patients to experience withdrawal symptoms for sever ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD

    SBC: CREATIVE BIO-PEPTIDES, INC.            Topic: NIA

    7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government